On Sept. 2, 2020, Mesoblast announced that it had received ethics approval to include Australian hospitals in the Phase 3 randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with acute respiratory distress syndrome (ARDS).

Participating hospitals in Melbourne and Sydney were been granted approval by the Human Research Ethics Committee of Monash Health and will join more than 17 leading U.S. medical centers already in the Phase 3 trial.